|
2014-12-08 |
2014-12-05 |
S
Venta
|
Lurker Nancy
Consejero no ejecutivo
|
35 673
+26.8%
166,91
3.287.116 US$
|
35 673
+26.8%
|
166,91
|
3.287.116 US$
|
|
|
2014-12-08 |
2014-12-05 |
S
Venta
|
Lurker Nancy
Consejero no ejecutivo
|
67 653
-48.8%
343,05
3.012.324 US$
|
67 653
-48.8%
|
343,05
|
3.012.324 US$
|
|
|
2014-12-08 |
2014-12-05 |
S
Venta
|
MCKEE WILLIAM
Consejero no ejecutivo
|
460
-39.4%
364,17
4.079.512 US$
|
460
-39.4%
|
364,17
|
4.079.512 US$
|
|
|
2014-12-08 |
2014-12-05 |
S
Venta
|
ADAMS ADRIAN
CEO and President
Consejero ejecutivo
|
40 000
-15.5%
33,97
1.358.704 US$
|
40 000
-15.5%
|
33,97
|
1.358.704 US$
|
|
|
2014-12-08 |
2014-12-05 |
S
Venta
|
FRIEDMAN PAUL A
Consejero no ejecutivo
|
9 689
-48.3%
33,85
327.953 US$
|
9 689
-48.3%
|
33,85
|
327.953 US$
|
|
|
2014-12-08 |
2014-12-04 |
S
Venta
|
FRIEDMAN PAUL A
Consejero no ejecutivo
|
20 000
-49.9%
33,67
673.452 US$
|
20 000
-49.9%
|
33,67
|
673.452 US$
|
|
|
2014-12-04 |
2014-12-03 |
S
Venta
|
FETZER OLIVER
Consejero no ejecutivo
|
50 000
-72.3%
34,00
1.700.000 US$
|
50 000
-72.3%
|
34,00
|
1.700.000 US$
|
|
|
2014-12-04 |
2014-12-02 |
S
Venta
|
CLASSON ROLF A
Consejero no ejecutivo
|
19 135
-65.7%
33,75
645.726 US$
|
19 135
-65.7%
|
33,75
|
645.726 US$
|
|
|
2014-12-04 |
2014-12-02 |
S
Venta
|
CLASSON ROLF A
Consejero no ejecutivo
|
260 000
-89.9%
33,81
8.790.808 US$
|
260 000
-89.9%
|
33,81
|
8.790.808 US$
|
|
|
2014-12-04 |
2014-12-02 |
S
Venta
|
FETZER OLIVER
Consejero no ejecutivo
|
50 000
-72.3%
34,03
1.701.635 US$
|
50 000
-72.3%
|
34,03
|
1.701.635 US$
|
|
|
2014-11-26 |
2014-11-25 |
S
Venta
|
JOBES ELIZABETH VARKI
Chief Compliance Officer
Oficial
|
23 750
-63.3%
34,03
808.310 US$
|
23 750
-63.3%
|
34,03
|
808.310 US$
|
|
|
2014-11-26 |
2014-11-25 |
S
Venta
|
JOBES ELIZABETH VARKI
Chief Compliance Officer
Oficial
|
4 052
-9.7%
34,05
137.964 US$
|
4 052
-9.7%
|
34,05
|
137.964 US$
|
|
|
2014-11-26 |
2014-11-25 |
S
Venta
|
Tursi James Patrick
Chief Medical Officer
Oficial
|
3 151
-9.0%
34,13
107.534 US$
|
3 151
-9.0%
|
34,13
|
107.534 US$
|
|
|
2014-11-26 |
2014-11-25 |
S
Venta
|
Tursi James Patrick
Chief Medical Officer
Oficial
|
10 562
-23.2%
34,12
360.394 US$
|
10 562
-23.2%
|
34,12
|
360.394 US$
|
|
|
2014-11-24 |
2014-11-21 |
S
Venta
|
KOVEN ANDREW I
EVP, CAO, GC and Secretary
Oficial
|
134 375
-77.6%
33,43
4.492.412 US$
|
134 375
-77.6%
|
33,43
|
4.492.412 US$
|
|
|
2014-11-24 |
2014-11-21 |
S
Venta
|
KOVEN ANDREW I
EVP, CAO, GC and Secretary
Oficial
|
5 308
-3.0%
33,44
177.518 US$
|
5 308
-3.0%
|
33,44
|
177.518 US$
|
|
|
2014-11-24 |
2014-11-21 |
S
Venta
|
Armstrong Jennifer Lou
Senior Vice President, HR
Oficial
|
69 412
-82.4%
33,50
2.325.031 US$
|
69 412
-82.4%
|
33,50
|
2.325.031 US$
|
|
|
2014-11-24 |
2014-11-21 |
S
Venta
|
Armstrong Jennifer Lou
Senior Vice President, HR
Oficial
|
6 391
-7.0%
33,50
214.075 US$
|
6 391
-7.0%
|
33,50
|
214.075 US$
|
|
|
2014-11-24 |
2014-11-21 |
S
Venta
|
Tursi James Patrick
Chief Medical Officer
Oficial
|
5 000
-12.5%
33,49
167.432 US$
|
5 000
-12.5%
|
33,49
|
167.432 US$
|
|
|
2014-11-24 |
2014-11-21 |
S
Venta
|
Tursi James Patrick
Chief Medical Officer
Oficial
|
3 648
-8.3%
33,45
122.011 US$
|
3 648
-8.3%
|
33,45
|
122.011 US$
|
|
|
2014-11-24 |
2014-11-20 |
S
Venta
|
WILLS ALAN
EVP, Corporate Development
Oficial
|
13 717
-30.9%
33,18
455.086 US$
|
13 717
-30.9%
|
33,18
|
455.086 US$
|
|
|
2014-11-24 |
2014-11-20 |
S
Venta
|
WILLS ALAN
EVP, Corporate Development
Oficial
|
142 875
-76.3%
33,18
4.740.207 US$
|
142 875
-76.3%
|
33,18
|
4.740.207 US$
|
|
|
2014-11-24 |
2014-11-20 |
S
Venta
|
Glickman Mark A
EVP - Sales and Marketing
Oficial
|
40 750
-59.3%
33,16
1.351.372 US$
|
40 750
-59.3%
|
33,16
|
1.351.372 US$
|
|
|
2014-11-24 |
2014-11-20 |
S
Venta
|
Glickman Mark A
EVP - Sales and Marketing
Oficial
|
7 202
-9.5%
33,18
238.963 US$
|
7 202
-9.5%
|
33,18
|
238.963 US$
|
|
|
2014-11-24 |
2014-11-20 |
S
Venta
|
Tursi James Patrick
Chief Medical Officer
Oficial
|
59 800
-57.8%
33,18
1.983.871 US$
|
59 800
-57.8%
|
33,18
|
1.983.871 US$
|
|
|
2014-11-24 |
2014-11-20 |
S
Venta
|
Tursi James Patrick
Chief Medical Officer
Oficial
|
6 200
-5.7%
32,94
204.253 US$
|
6 200
-5.7%
|
32,94
|
204.253 US$
|
|
|
2014-03-17 |
2014-03-14 |
S
Venta
|
DEL TITO BENJAMIN J JR
EVP, Reg Affairs & Project Mgt
Oficial
|
524
-8.3%
29,55
15.484 US$
|
524
-8.3%
|
29,55
|
15.484 US$
|
|
|
2014-03-17 |
2014-03-14 |
S
Venta
|
DEL TITO BENJAMIN J JR
EVP, Reg Affairs & Project Mgt
Oficial
|
883
-12.3%
29,55
26.093 US$
|
883
-12.3%
|
29,55
|
26.093 US$
|
|
|
2014-03-17 |
2014-03-14 |
S
Venta
|
DEL TITO BENJAMIN J JR
EVP, Reg Affairs & Project Mgt
Oficial
|
30 625
-57.4%
29,50
903.438 US$
|
30 625
-57.4%
|
29,50
|
903.438 US$
|
|
|
2014-03-06 |
2014-03-05 |
S
Venta
|
CLASSON ROLF A
Consejero no ejecutivo
|
10 000
-30.4%
31,85
318.477 US$
|
10 000
-30.4%
|
31,85
|
318.477 US$
|
|
|
2013-12-16 |
2013-12-13 |
Por favor
Venta prevista
|
DEL TITO BENJAMIN J JR
EVP, Reg Affairs & Project Mgt
Oficial
|
302
-6.9%
20,50
6.191 US$
|
302
-6.9%
|
20,50
|
6.191 US$
|
|
|
2013-12-16 |
2013-12-13 |
S
Venta
|
DEL TITO BENJAMIN J JR
EVP, Reg Affairs & Project Mgt
Oficial
|
4 300
-49.6%
20,50
88.150 US$
|
4 300
-49.6%
|
20,50
|
88.150 US$
|
|
|
2013-12-12 |
2013-12-11 |
Por favor
Venta prevista
|
Fickenscher James E
Chief Financial Officer
Oficial
|
71 067
-61.2%
20,37
1.447.450 US$
|
71 067
-61.2%
|
20,37
|
1.447.450 US$
|
|
|
2013-05-22 |
2013-05-20 |
S
Venta
|
MCKEE WILLIAM
Consejero no ejecutivo
|
2 000
-20.0%
15,10
30.209 US$
|
2 000
-20.0%
|
15,10
|
30.209 US$
|
|
|
2012-06-26 |
2012-06-25 |
Por favor
Venta prevista
|
DEL TITO BENJAMIN J JR
EVP, Reg Affairs & Project Mgt
Oficial
|
12 682
-73.9%
25,01
317.155 US$
|
12 682
-73.9%
|
25,01
|
317.155 US$
|
|
|
2012-06-08 |
2012-06-06 |
S
Venta
|
DEL TITO BENJAMIN J JR
EVP, Reg Affairs & Project Mgt
Oficial
|
5 700
-73.8%
22,55
128.536 US$
|
5 700
-73.8%
|
22,55
|
128.536 US$
|
|
|
2012-06-08 |
2012-06-06 |
S
Venta
|
DEL TITO BENJAMIN J JR
EVP, Reg Affairs & Project Mgt
Oficial
|
300
-3.7%
22,55
6.766 US$
|
300
-3.7%
|
22,55
|
6.766 US$
|
|
|
2012-03-01 |
2012-02-28 |
B
Compra
|
Brandt Peter C.
Consejero no ejecutivo
|
9 700
+3233.3%
20,10
194.970 US$
|
9 700
+3233.3%
|
20,10
|
194.970 US$
|
|
|
2012-03-01 |
2012-02-28 |
B
Compra
|
Brandt Peter C.
Consejero no ejecutivo
|
300
+inf%
20,09
6.028 US$
|
300
+inf%
|
20,09
|
6.028 US$
|
|
|
2011-11-07 |
2011-11-03 |
B
Compra
|
Fickenscher James E
Chief Financial Officer
Oficial
|
1 610
+6.4%
15,54
25.024 US$
|
1 610
+6.4%
|
15,54
|
25.024 US$
|
|
|
2011-10-11 |
2011-10-07 |
Por favor
Venta prevista
|
ANIDO ARMANDO
CEO & President
Consejero ejecutivo
|
5 275
-27.9%
14,23
75.046 US$
|
5 275
-27.9%
|
14,23
|
75.046 US$
|
|
|
2011-08-03 |
2011-08-02 |
S
Venta
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
40 781
-0.7%
17,25
703.391 US$
|
40 781
-0.7%
|
17,25
|
703.391 US$
|
|
|
2011-08-03 |
2011-08-02 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
1 001
-0.7%
17,25
17.265 US$
|
1 001
-0.7%
|
17,25
|
17.265 US$
|
|
|
2011-08-03 |
2011-08-02 |
S
Venta
|
Baker / Tisch Capital (GP), LLC
Gran accionista
|
507
-0.7%
17,25
8.745 US$
|
507
-0.7%
|
17,25
|
8.745 US$
|
|
|
2011-08-03 |
2011-08-02 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
6 361
-0.7%
17,25
109.715 US$
|
6 361
-0.7%
|
17,25
|
109.715 US$
|
|
|
2011-08-03 |
2011-08-01 |
S
Venta
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
394 404
-6.7%
18,04
7.114.614 US$
|
394 404
-6.7%
|
18,04
|
7.114.614 US$
|
|
|
2011-08-03 |
2011-08-01 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
9 678
-6.7%
18,04
174.580 US$
|
9 678
-6.7%
|
18,04
|
174.580 US$
|
|
|
2011-08-03 |
2011-08-01 |
S
Venta
|
Baker / Tisch Capital (GP), LLC
Gran accionista
|
4 902
-6.7%
18,04
88.427 US$
|
4 902
-6.7%
|
18,04
|
88.427 US$
|
|
|
2011-08-03 |
2011-08-01 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
61 519
-6.7%
18,04
1.109.735 US$
|
61 519
-6.7%
|
18,04
|
1.109.735 US$
|
|
|
2011-08-03 |
2011-08-01 |
S
Venta
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
260 868
-4.3%
18,03
4.703.320 US$
|
260 868
-4.3%
|
18,03
|
4.703.320 US$
|
|
|
2011-08-03 |
2011-08-01 |
S
Venta
|
14159 capital (GP), LLC
Gran accionista
|
6 400
-4.3%
18,03
115.389 US$
|
6 400
-4.3%
|
18,03
|
115.389 US$
|
|
|
2011-08-03 |
2011-08-01 |
S
Venta
|
Baker / Tisch Capital (GP), LLC
Gran accionista
|
3 243
-4.3%
18,03
58.470 US$
|
3 243
-4.3%
|
18,03
|
58.470 US$
|
|
|
2011-08-03 |
2011-08-01 |
S
Venta
|
Baker Biotech Capital (GP), LLC
Gran accionista
|
40 690
-4.3%
18,03
733.620 US$
|
40 690
-4.3%
|
18,03
|
733.620 US$
|
|
|
2011-07-12 |
2011-07-08 |
Por favor
Venta prevista
|
ANIDO ARMANDO
CEO & President
Consejero ejecutivo
|
5 275
-27.9%
20,30
107.101 US$
|
5 275
-27.9%
|
20,30
|
107.101 US$
|
|
|
2011-03-31 |
2011-03-30 |
B
Compra
|
14159 capital (GP), LLC
Gran accionista
|
3 911
+2.7%
21,98
85.963 US$
|
3 911
+2.7%
|
21,98
|
85.963 US$
|
|
|
2011-03-31 |
2011-03-30 |
B
Compra
|
Baker Bros. Capital (GP), LLC
Gran accionista
|
309
+4.6%
21,98
6.792 US$
|
309
+4.6%
|
21,98
|
6.792 US$
|
|
|
2011-03-31 |
2011-03-29 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
82 000
+1.4%
21,94
1.798.670 US$
|
82 000
+1.4%
|
21,94
|
1.798.670 US$
|
|
|
2011-03-31 |
2011-03-29 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
250 000
+4.3%
22,00
5.499.400 US$
|
250 000
+4.3%
|
22,00
|
5.499.400 US$
|
|
|
2011-03-10 |
2011-03-09 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
550 000
+10.5%
22,75
12.513.765 US$
|
550 000
+10.5%
|
22,75
|
12.513.765 US$
|
|
|
2011-03-10 |
2011-03-09 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
115 000
+2.3%
23,44
2.695.060 US$
|
115 000
+2.3%
|
23,44
|
2.695.060 US$
|
|
|
2011-03-10 |
2011-03-09 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
117 273
+2.3%
23,17
2.717.344 US$
|
117 273
+2.3%
|
23,17
|
2.717.344 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
58 388
+1.2%
22,81
1.331.976 US$
|
58 388
+1.2%
|
22,81
|
1.331.976 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
1 948
+0.0%
22,51
43.845 US$
|
1 948
+0.0%
|
22,51
|
43.845 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
48 657
+1.0%
22,86
1.112.299 US$
|
48 657
+1.0%
|
22,86
|
1.112.299 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
86 227
+1.8%
22,88
1.972.693 US$
|
86 227
+1.8%
|
22,88
|
1.972.693 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
14159 capital (GP), LLC
Gran accionista
|
1 612
+1.1%
22,81
36.774 US$
|
1 612
+1.1%
|
22,81
|
36.774 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
14159 capital (GP), LLC
Gran accionista
|
54
+0.0%
22,51
1.215 US$
|
54
+0.0%
|
22,51
|
1.215 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
14159 capital (GP), LLC
Gran accionista
|
1 343
+0.9%
22,86
30.701 US$
|
1 343
+0.9%
|
22,86
|
30.701 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
14159 capital (GP), LLC
Gran accionista
|
2 380
+1.7%
22,88
54.449 US$
|
2 380
+1.7%
|
22,88
|
54.449 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
Baker Brothers Life Sciences Capital (GP), LLC
Gran accionista
|
10 996
+0.2%
23,05
253.503 US$
|
10 996
+0.2%
|
23,05
|
253.503 US$
|
|
|
2011-03-10 |
2011-03-08 |
B
Compra
|
14159 capital (GP), LLC
Gran accionista
|
304
+0.2%
23,05
7.008 US$
|
304
+0.2%
|
23,05
|
7.008 US$
|
|
|
2011-03-09 |
2011-03-08 |
Por favor
Venta prevista
|
ANIDO ARMANDO
CEO & President
Consejero ejecutivo
|
5 275
-24.7%
23,03
121.502 US$
|
5 275
-24.7%
|
23,03
|
121.502 US$
|
|
|
2011-03-09 |
2011-03-08 |
Por favor
Venta prevista
|
ANIDO ARMANDO
CEO & President
Consejero ejecutivo
|
5 280
-24.7%
23,01
121.492 US$
|
5 280
-24.7%
|
23,01
|
121.492 US$
|
|
|
2011-01-12 |
2011-01-10 |
Por favor
Venta prevista
|
ANIDO ARMANDO
CEO & President
Consejero ejecutivo
|
5 275
-24.7%
23,27
122.723 US$
|
5 275
-24.7%
|
23,27
|
122.723 US$
|
|
|
2011-01-12 |
2011-01-10 |
Por favor
Venta prevista
|
ANIDO ARMANDO
CEO & President
Consejero ejecutivo
|
5 280
-24.7%
23,17
122.327 US$
|
5 280
-24.7%
|
23,17
|
122.327 US$
|
|